Cardiovascular in-licensing play Kardigan looking for quick path to IPO: Finance Report

With three programs that have generated clinical data, cardiovascular company Kardigan is aiming to execute an IPO less than three years after its incorporation, making it the latest well-funded biotech to seek a short path to the public markets.

Kardigan Inc. filed a prospectus late Tuesday for a NASDAQ offering that would follow its announcements of two nine-digit venture rounds in 2025: a  $300 million series A as the year began, and a $254 million series B in October...